Novel serum tumor marker, RCAS1, in pancreatic diseases

Table 1 Diagnosis of malignant and benign diseases by serum RCAS1, CEA and CA19-9

	RCAS1 (%)		CEA (%)		CA19-9 (%)		RCAS1+CEA (%)		RCAS1+CA19-9 (%)		CA19-9+CEA (%)
	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
Malignant	12	10	6	16	16	6	13	9	21	1	18	4
Benign	3	33	2	34	8	28	5	31	11	25	9	27
Sensitivity	553		27b2		731		592		95b3		82d
Specificity	92		94		78		86		69		75
Positive predictive value	80		75		67		72		66		67
Negative predictive value	78		68		82		78		96		87
Efficiency	78		69		76		76		79		78

^bP<0.001 vs RCAS1+CA19-9;

^dP<0.001 vs CA19-9+CEA; ¹P = 0.003 vs CA19-9;

²P = 0.033 vs RCAS1+CEA;

³P = 0.002 vs RCAS1+CA19-9.

Table 2 Tumor stage and serum RCAS1, CEA and CA19-9

Stage	RCAS1		CEA		CA19-9		RCAS1+CEA		RCAS1+CA19-9		CA19-9+CEA
	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
1	1	0	0	1	0	1	1	0	1	0	0	1
3	0	1	0	1	1	0	0	1	1	0	1	0
4A	0	3	0	3	3	0	0	3	3	0	3	0
4B	11	6	6	11	12	5	12	5	16	1	14	3

Table 3 Unresectability and serum RCAS1, CEA and CA19-9

Unresectability	RCAS1 (%)		CEA (%)		CA19-9 (%)		RCAS1+CEA (%)		RCAS1+CA19-9 (%)		CA19-9+CEA (%)
	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
Yes	11	6	6	11	12	5	12	5	16	1	14	3
No	1	4	0	5	4	1	1	4	5	0	4	1
Sensitivity	65		35123		712		713		94b		821
Specificity	80		1004		20		80		0		20
Positive predictive value	92		100		75		92		76		78
Negative predictive value	40		31		17		44		0		25
Efficiency	68		50		59		73		73		68

¹P = 0.005 vs CA19-9+CEA;

^bP<0.001 vs RCAS1+CA19-9;

²P = 0.039 vs CA19-9;

³P = 0.039 vs RCAS1+CEA; ⁴P = 0.011 vs RCAS1+CA19-9.

Table 4 Recurrence and serum RCAS1, CEA and CA19-9

Recurrence	RCAS1 (%)		CEA (%)		CA19-9 (%)		RCAS1+CEA (%)		RCAS1+CA19-9 (%)		CA19-9+CEA (%)
	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
Yes	2	0	1	1	2	0	2	0	2	0	2	0
No	1	12	2	11	1	12	3	10	1	12	3	10
Sensitivity	100		50		100		100		100		100
Specificity	92		85		92		77		92		77
Positive predictive value	67		33		67		40		67		40
Negative predictive value	100		92		100		100		100		100
Efficiency	93		80		93		80		93		80